scholarly journals Effects of Nighttime Single-Dose Administration of Vasodilating vs Sympatholytic Antihypertensive Agents on Sleep Blood Pressure in Hypertensive Patients With Sleep Apnea Syndrome

2014 ◽  
Vol 16 (6) ◽  
pp. 459-466 ◽  
Author(s):  
Kazuomi Kario ◽  
Mitsuo Kuwabara ◽  
Satoshi Hoshide ◽  
Michiaki Nagai ◽  
Masahisa Shimpo
Keyword(s):  
Blood Pressure ◽  
Single Dose ◽  
Sleep Apnea ◽  
Sleep Apnea Syndrome ◽  
Antihypertensive Agents ◽  
Dose Administration ◽  
Hypertensive Patients ◽  
Single Dose Administration ◽  
Apnea Syndrome

Abstract 14387: Dose-Related Reductions in Blood Pressure With a RNA Interference (RNAi) Therapeutic Targeting Angiotensinogen in Hypertensive Patients: Interim Results From a First-In-Human Phase 1 Study of ALN-AGT01

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Stephen A Huang ◽  
Jorg Taubel ◽  
Giuseppe Fiore ◽  
Peter Dewland ◽  
George L Bakris ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Single Dose ◽  
Adverse Events ◽  
Phase 1 ◽  
Serious Adverse Events ◽  
Therapeutic Targeting ◽  
Dose Administration ◽  
Hypertensive Patients ◽  
Single Dose Administration ◽  
Angiotensin Peptides

Background: Angiotensinogen (AGT) is the sole precursor of all angiotensin peptides and plays a key role in hypertension pathogenesis. We evaluated the effect of ALN-AGT01, a subcutaneous investigational RNAi therapeutic targeting hepatic AGT synthesis, on blood pressure in hypertensive patients. Methods: As part of a phase 1 program designed to assess the safety and tolerability of ALN-AGT01, we conducted a multicenter study randomizing patients aged 18-65 years with mild to moderate hypertension (mean seated systolic blood pressure [SBP] of >130 and ≤165 mmHg after washout of antihypertensive medication) 2:1 to ascending single doses of ALN-AGT01 or placebo. Change from baseline in BP at 8 weeks was measured by ambulatory BP monitoring (ABPM). We report interim results as of May 14, 2020. Results: Sixty patients (mean age 52 years, 45% female, mean baseline 24h SBP 139 +/- 7 mm Hg) were enrolled in ascending dose cohorts of 10 mg, 25 mg, 50 mg, 100 mg, or 200 mg. Dose-related reductions in serum AGT levels were observed (figure), with reductions >90% in the 100 and 200 mg dose cohorts. AGT remained durably reduced through 12 weeks after single dose administration. Concomitant reductions in BP from baseline were observed with AGT knockdown, with an over 10 mm Hg reduction of mean 24-hour SBP observed at Week 8 after single doses of 100 mg or 200 mg. No symptomatic hypotension, treatment-related serious adverse events, or clinically significant elevations in blood creatinine or potassium were seen. Conclusions: Single dose administration of ALN-AGT01 to hypertensive patients resulted in dose-related reductions in serum AGT and BP over 8 weeks without hypotension or other related serious adverse events. Durable AGT knockdown to 12 weeks supports further evaluation of once quarterly or potentially less frequent dose administration.

Profile Of Blood Pressure, Circadian Rythm And Risk Factors In Hypertensive Patients With And Without Sleep Apnea Syndrome

2011 ◽  
Author(s):  
Enrique J. Soto Hurtado ◽  
Jose M. Garcia Jimenez ◽  
Francisco Paez Codeso ◽  
Julio Torres Jimenez ◽  
Francisca Rius Diaz ◽  
...  
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Sleep Apnea ◽  
Sleep Apnea Syndrome ◽  
Hypertensive Patients ◽  
Apnea Syndrome ◽  
Circadian Rythm

scholarly journals THE BENEFITS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS I TYPE IN HYPERTENSIVE PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME

2013 ◽  
Vol 19 (2) ◽  
pp. 156-163
Author(s):  
Yu. V. Sviryaev ◽  
N. E. Zvartau ◽  
L. S. Korostovtseva ◽  
A. L. Kalinkin ◽  
A. O. Konradi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Angiotensin Ii ◽  
Obstructive Sleep Apnea Syndrome ◽  
Sleep Apnea Syndrome ◽  
Angiotensin Ii Receptor ◽  
Hypertensive Patients ◽  
Obstructive Sleep ◽  
Apnea Syndrome

Objective.To assess efficiency of angiotensin II converting enzyme inhibitor Perindopril versus angiotensin II receptor blocker Telmisartan in hypertensive patients with obstructive sleep apnea syndrome (OSAS).Design and methods.Sixty hypertensive patients with OSAS (non-CPAP-users) were enrolled in a randomized controlled open study: 48 males and 12 females; mean age — 56,2 ± 9,5 years; hypertension duration — 12,5 ± 7,4 years; body mass index — 32,0 ± 5,9 kg/m2, apnea-hypopnea index (AHI) — 35,4 ± 24,2 episodes per hour of sleep. All patients were divided into 2 groups: patients (n = 30) from the 1st group got Telmisartan 40 mg daily (titrated up to 80 mg daily if necessary), and Perindopril 4 mg daily (titrated up to 8 mg daily) was prescribed to 2nd group (n = 30). The treatment lasted for 12 weeks. Results.Twenty three patients in Telmisartan group and 24 patients in Perindopril group achieved goal blood pressure (< 140/90 mmHg) (χ2 = 1,23; p > 0,05), all patients got maximal doses of medications. The reduction of offi ce and 24-hour blood pressure was comparable in both groups. Circadian blood pressure profi le was normalized in 17 patients from Telmisartan group and in 9 patients from Perindopril group (χ2 = 6,21; p < 0,05). At the same time AHI decreased by 19 episodes per hour of sleep in Telmisartan group, while it increased by 10,1 episodes per hour of sleep in Perindopril group (p < 0,01).Conclusion.Telmisartan treatment is beneficial in hypertensive obese patients with OSAS compared to Perindopril due to the reduction of OSAS severity (assessed by AHI) leading to the normalization of circadian blood pressure profile. 

Short-term blood pressure variability in hypertensive patients with obstructive sleep apnea syndrome

2014 ◽  
Vol 13 (2) ◽  
pp. 117-126 ◽  
Author(s):  
Nobuo Sasaki ◽  
Ryoji Ozono ◽  
Yoshinobu Edahiro ◽  
Tomomi Okita ◽  
Kazushi Teramen ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Obstructive Sleep Apnea Syndrome ◽  
Blood Pressure Variability ◽  
Sleep Apnea Syndrome ◽  
Short Term ◽  
Hypertensive Patients ◽  
Obstructive Sleep ◽  
Apnea Syndrome

CARDIOVASCULAR RISKS IN OBSTRUCTIVE SLEEP APNEA SYNDROME WITH IMPROVED SASD07 COMPARE TO STARDUST II

2014 ◽  
pp. 77-86
Author(s):  
Anh Tien Hoang ◽  
Thi Y Nhi Nguyen ◽  
Luu Trinh Nguyen ◽  
Thi Hong Diep Phan ◽  
Huu Cat Nguyen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Cardiovascular Risk ◽  
Sleep Apnea ◽  
Sleep Apnea Syndrome ◽  
Hdl Cholesterol ◽  
Control Group ◽  
Positive Correlation ◽  
Obstructive Sleep ◽  
Apnea Syndrome

Background : Sleep Apnea Syndrome (SAS) is a cause of hypertension, increasingcardiovascular risk and cardiovascular disease such as stroke, coronary artery disease, myocardial infarction, arrhythmias, heart failure, increasing the risk of death in patients with heart disease, independent of other causative factors. So far, in Vietnam there are very few studies on Obstructive Sleep Apnea Syndrome (OSAS) and cardiovascular risk factors . Self-making SASD07 is trustly for detecting OSAS with statistical significiant in comparision with StarDustII (gold criteria). Subjects and Methods: Cross sectional study, comparision with control group: 136 peoples (68 in disease group and 68 in control group). Patients were parallelly measured with StarDustII and SASD07 to detect OSAS and find the corellation with cardiovascular risk factors. Results: There is a positive correlation between SBP with the severity of OSAS (r = 0.459, p < 0.001), positive correlation between DBP with the severity of OSAS (r = 0.352, p < 0.003). No statistically significant differences between severe OSAS and fasting blood glucose, cholesterol, HDL Cholesterol, Non - HDL Cholesterol, LDL Cholesterol and TG median (p > 0.05). There is a positive correlation between AHI and neck circumference (r = 0.511, p < 0.001), waist circumference (r = 0.585, p < 0.001), BMI (r = 0.380, p < 0.01). SASD07 diagnostic value of detecting OSAS compared with StarDustII have Kappa = 0.72, (standard error 0.06, p <0.001). Conclusion: The risk factors related to OSAS in our study is neck circumference, waist circumference, systolic blood pressure, diastolic blood pressure. SASD07 have a good value in diagnosing of OSAS compared with polysomnography StarDustII. Key words: Sleep Apnea Syndrome, cardiovascular risk factor, SASD07.

scholarly journals 0210 : Obstructive sleep apnea syndrome in hypertensive patients

2016 ◽  
Vol 8 (3) ◽  
pp. 245-246
Author(s):  
Dalila El Baghdadi ◽  
Ghita Mouhsine ◽  
Safaa Raboukhi ◽  
Leila Azzouzi ◽  
Rachida Habbal
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Obstructive Sleep Apnea Syndrome ◽  
Sleep Apnea Syndrome ◽  
Hypertensive Patients ◽  
Obstructive Sleep ◽  
Apnea Syndrome
Sign in / Sign up

Export Citation Format

Share Document